Self-reports of taste impairment among patients with long-haul COVID-19 infection were overestimated, according to findings from a research letter published in JAMA Otolaryngology.
Between March and July 2021, investigators screened all patients referred to the outpatient clinic of Trieste University Hospital in Italy for postCOVID-19 chemosensory disorders. Eligible patients included those who were aged 18 years and older, had reverse transcription polymerase chain reaction (RT-PCR)-confirmed SARS-CoV-2 infection, had self-reported an altered sense of taste more than 3 months after the acute phase of COVID-19 infection, and had undergone psychophysical evaluation, including orthonasal and retronasal olfactory testing and gustatory assessment.
A total of 105 patients were included in the final analysis. Olfactory and gustatory function were assessed via validated extended Sniffin’ Sticks test battery (Burghart Messtechnik, Wedel, Germany) and validated Taste Strips test (Burghart Messtechnik, Wedel, Germany), respectively. Retronasal olfactory function was assessed via 20 powdered tasteless aromas (Givaudan Schweiz AG, Dubendorf, Switzerland). A threshold, discrimination, and identification (TDI) score was used to determine normosmia (TDI ≥30.75), hyposmia (TDI, 16.25-30.5), and anosmia (TDI ≤16.0); and a Taste Strips Score (TSS) was calculated to identify hypogeusia (TSS <9 points) and normogeusia (TSS ≥9 points).
Among patients included in the study, the median age was 45 (range 20-76) years, 103 (98.1%) had symptomatic mild COVID-19 infection with no evidence of pneumonia, 80 (76.2%) were women, and 99 (94.3%) self-reported an associated olfactory impairment. Psychophysical evaluations occurred at a median of 226 (range, 94-439) days after the onset of infection.
On analysis of TSS, the investigators found that the prevalence of hypogeusia was 41.9%, which decreased to 28.6% after stratification by patient age. Of note, only 3 (2.9%) patients had confirmed hypogeusia and were normosmic on psychophysical evaluation. The investigators noted that as TDI increased, the prevalence of patients who were normogeusic also increased. Of 61 patients who were found to be normogeusic on psychophysical evaluation, 51 (83.6%) had a TDI score of less than 30.75, 16 (26.2%) had a retronasal score of less than 12, and 10 (16.4%) had both normal orthonasal and retronasal olfactory function.
Study limitations included a lack of testing during the acute phase of COVID-19, that patients were tested at different timepoints and in the absence of an age-matched control group. The investigators noted that, “…questions on taste function are not validated tools and can be misleading.” False-negatives may result from the use of a single sensory technique to assess taste function. Dysgeusia, phantogeusia, parosmia, and phantosmia were not addressed in this study, thus results may not be generalizable to other patient populations.
According to the investigators, “…this psychophysical study uncovers overestimation of self-reported taste impairment and supports the use of validated psychophysical tests to estimate the burden of chemosensory dysfunction in people with long-[haul] COVID-19.”
Disclosure: One author declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.
Boscolo-Rizzo P, Hummel T, Hopkins C, et al. Comprehensive chemosensory psychophysical evaluation of self-reported gustatory dysfunction in patients with long-term COVID-19: A cross-sectional study. JAMA Otolaryngol Head Neck Surg. Published online January 6, 2022. doi: 10.1001/jamaoto.2021.3993.
This article originally appeared on Infectious Disease Advisor